Loading...
•
Dec 31, 2019
Pacira Q4 2019 Earnings Report
Pacira reported record revenues and non-GAAP net income increased.
Key Takeaways
Pacira BioSciences, Inc. reported a 29% increase in total revenues for the fourth quarter of 2019, reaching $122.4 million, driven by a 24% increase in EXPAREL net product sales and iovera° net product sales of $3.2 million. The company's GAAP net loss was $4.9 million, or $0.12 per share, while non-GAAP net income was $23.8 million, or $0.56 per share. Pacira also provided full-year 2020 revenue guidance of between $485 million and $500 million.
Total revenues increased by 29% to $122.4 million compared to Q4 2018.
EXPAREL net product sales increased by 24% to $116.9 million compared to Q4 2018.
iovera° net product sales were $3.2 million.
Non-GAAP net income was $23.8 million, or $0.56 per diluted share.
Revenue by Segment
Forward Guidance
Pacira provided full-year 2020 financial guidance, expecting total revenues to be between $485 million and $500 million.
Positive Outlook
- Total revenues to be between $485 million and $500 million
- EXPAREL net product sales to be between $465 million and $475 million
- iovera° net product sales to be between $15 million and $20 million
- Non-GAAP gross margins to be between 76% and 78%
Challenges Ahead
- Non-GAAP research and development (R&D) expense to be between $60 million to $70 million
- Non-GAAP selling, general and administrative (SG&A) expense to be between $180 million and $190 million
- Stock-based compensation to be between $35 million and $40 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...